Cambridge Cognition Share Discussion Threads

[cheshire man] 26/6/2014 07:13

And I thought I was early :-)

[battlebus2] 19/6/2014 08:36

Hopefully we can benefit from the governments new focus on dementia to be announced today.

[marben100] 17/6/2014 12:14

COG are presenting at the ShareSoc growth company seminar on 25th June. See for details and to register. Only a few places left, so register ASAP if you'd like to attend!

Cheers,

Mark
Twitter @marben100, @ShareSocUK

[battlebus2] 16/6/2014 15:26

Very illiquid with only 20% in public hands and with no buyers the spread is widening with every sell.

[battlebus2] 06/6/2014 16:26

Beggars belief at times this stock market. Some selling on the good contract news but as ever this is a long game and I intend to see these trading At £1 plus.

[battlebus2] 06/6/2014 15:12

Seems to be a seller around to spoil the fun here.

[battlebus2] 05/6/2014 18:00

Thanks for the Finn cap note Cheshire Man, hopefully the Sharesoc presentation will bring us to the attention of a few more investors.
It's a shame we didn't finish the day blue.

[cheshire man] 05/6/2014 17:57

ShareSoc Company Seminar Announcement



The line-up for our next seminar at which public companies will be presenting on the 25th June is now complete and is given below. This event is in the City of London, with registration starting at 4.00 pm. Four companies will be presenting this month and answering your questions, which are:



- Cambridge Cognition (COG): Cognitive assessment software for use in clinical trials, research and healthcare provision.

[cheshire man] 05/6/2014 10:23

Finncap retains £1 tp "with comfort" :-)


Major Cantab Solutions contract CORP
A £1.6m contract to provide cognitive safety assessment on a Phase III trial
of a cardiovascular drug has been signed. Whilst we are making no
changes to our forecasts, this major contract provides confidence in our
full-year estimates.
􀀗Contract details. The contract, totalling £1.6m, is to provide cognitive testing
support for a global multi-year Phase III study of a cardiovascular drug being
developed by an unnamed major biopharmaceutical company. The cognitive
testing is to evaluate the CNS safety of the drug.
􀀗Implications. Increasingly, there is a regulatory requirement to assess
cognitive side effects of drugs, even if they are not indicated for a CNS
condition, and this contract illustrates that Cambridge Cognition's battery of
cognitive function tests can be deployed in such a way in a highly regulated
environment. Cambridge Cognition anticipates that £0.8m of revenue will be
recognised in the current financial year. Whilst we make no changes to our
forecasts, this contract provides us with comfort in our £2.8m revenue forecast
for Cantab Solutions this year.

[cheshire man] 05/6/2014 07:55

Nice news for us this morning :-)

[battlebus2] 05/6/2014 07:33

Morning janeann, given turnover last year was 4 million this is a sizeable contract win. Worth a small punt under 70p imv.

[janeann] 05/6/2014 07:27

That does look positive battlebus. I hadn't considered that angle for COGs tests; I was less positive on the early dementia screening as I am not certain how the results might be used, but will look a little more closely at this company now.

[sharesoc] 30/5/2014 11:52

Shareholders and potential investors in Cambridge Cognition will probably be interested in attending ShareSoc's growth company seminar where COG will be presenting. More at: hxxp://www.sharesoc.org/seminarjune2014.html

[cheshire man] 28/5/2014 08:47

Beat me to it bb:-)

[battlebus2] 28/5/2014 07:12

More good news this morning....

Cantab Mobile rolled out in North East Lincolnshire CCG

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces that North East Lincolnshire Clinical Commissioning Group ('CCG') has recently introduced the Cantab Mobile app in five GP surgeries, five pharmacies and Grimsby hospital to help diagnose dementia earlier.

North East Lincolnshire is the latest CCG to roll out Cantab Mobile into GP surgeries, pharmacies and hospitals making the total number of CCGs rolled out in the UK 28. This technology has been introduced as part of a three-month evaluation. Cantab Mobile is the leading medical software for primary care allowing doctors to detect the earliest signs of clinically relevant memory problems by asking the patients to remember and match different shapes and patterns that appear on the iPad.

In April 2013 the Company announced the specifications from the NHS Commissioning Board for the four new directed enhanced services ('DES') that were to be offered to GP practices in 2013/14. For dementia this has now been extended into 2014/15. The specification prioritises, amongst other conditions, the timely diagnosis and support for people with dementia. This means that by rolling out Cantab Mobile the GP surgeries can expect to receive financial incentives to test anyone in the community, encouraging earlier diagnosis in the community.

Commenting, Nick Kerton, Chief Executive Officer of Cambridge Cognition, said: "Dementia currently costs the UK over £2.3 billion a year and if we are going to reduce this figure, early diagnosis is key. We are therefore extremely pleased that North East Lincolnshire has adopted Cantab Mobile to improve diagnosis rates in the area."

[battlebus2] 24/5/2014 12:32

Featured in Shares magazine this week. Positive article and states we should produce a maiden profit next year.

[battlebus2] 14/5/2014 09:05

Sharesoc growth company event has COG attending, the new date is 25th June.

[battlebus2] 08/5/2014 07:07

Fairly upbeat...AGM Statement

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, will hold its Annual General Meeting today at 10.00am at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ.

At the meeting Nick Kerton, Chief Executive Officer, will provide shareholders with the following update:

As I outlined in our Preliminary Results statement the business now has a clear strategic focus and we have in place a commercial infrastructure which will allow us to convert our wealth of scientific know-how into sustainable and growing commercial sales.

We have had a positive start to trading in the first quarter of the new financial year and remain confident that we will return the business to growth in 2014.

[sharesoc] 07/4/2014 10:13

Reminder that shareholders and potential investors in Cambridge Cognition will probably be interested in attending this event on the Sharesoc website: www.sharesoc.org/seminarmay2014.html

[battlebus2] 02/4/2014 07:10

Directorate Change

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces the appointment of Michael Lewis as Non-Executive Chairman. Michael joined the Board of Cambridge Cognition in 2013 as a Non-Executive Director and has gained over 25 years' experience in the global health and pharma industry.

Dr Jane Worlock, currently Non-Executive Chairman of the Company, has given notice to the Company of her intention to resign and will step down from the conclusion of the Company's forthcoming AGM, at which point Michael Lewis' appointment will take effect.

[battlebus2] 01/4/2014 23:01

Good to see them presenting and helping raise their profile to potential investors.